153465-65-7

Upstream product

• 133240-06-9 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 167374-83-6 2-(6-bromomethyl-quinolin-2-yl)-benzoic acid methyl ester 
• 608-05-9 5-methyl-indole-2,3-dione 
• 153465-52-2 2-(6-methylquinolin-2-yl)benzoic acid 
• 153465-51-1 methyl 2-(6-methylquinolin-2-yl)benzoate 
• 153465-48-6 2-(2-carboxyphenyl)-6-methyl-4-quinoline-carboxylic acid 

Downstream Products

• 153465-67-9 sodium 2-{6-[(2-ethyl-5,7-dimethyl-3H-imidazo-[4,5-b]pyridin-3-yl)methyl]quinolin-2-yl}benzoate 
• 194347-19-8 2-{6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]quinolin-2-yl}aniline 

Relevant academic research and scientific papers

A novel trifluoromethanesulfonamidophenyl-substituted quinoline derivative, GA 0113: Synthesis and pharmacological profiles

The trifluoromethanesulfonamidophenyl-substituted quinoline GA 0113 have been synthesized from o-nitrobenzoyl chloride via a multi-step process. GA 0113 displaced specific binding of [125I]-Sar1, Ile8-Ang II to AT1 receptors in membrane from Sf9 cells. In concious normotensive dogs, GA 0113 inhibited the Ang II-induced pressor response with ID50 of 0.032mg/kg and dose-dependently increased plasma renin activity for 48h.

Quinoline compounds

A quinoline compound represented by the formula (1) or a salt thereof: STR1 wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.